Abstract
Hyperkalemia is a frequently detected electrolyte abnormality that can cause life-threatening complications. Hyperkalemia is most often the result of intrinsic (decreased glomerular filtration rate; selective reduction in distal tubule secretory function; impaired mineralocorticoid activity; and metabolic disturbances, such as acidemia and hyperglycemia) and extrinsic factors (e.g., drugs, such as renin-angiotensin-aldosterone system inhibitors, and potassium intake). The frequent use of renin-angiotensin-aldosterone system inhibitors in patients who are already susceptible to hyperkalemia (e.g., patients with chronic kidney disease, diabetes mellitus, or congestive heart failure) contributes to the high incidence of hyperkalemia. There is a need to understand the causes of hyperkalemia and to be aware of strategies addressing the disorder in a way that provides the most optimal outcome for affected patients. The recent development of 2 new oral potassium-binding agents has led to the emergence of a new paradigm in the treatment of hyperkalemia.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 164-170 |
| Number of pages | 7 |
| Journal | Kidney International Supplements |
| Volume | 7 |
| Issue number | 3 |
| DOIs | |
| State | Published - Dec 1 2017 |
Fingerprint
Keywords
- chronic kidney disease
- hyperkalemia
- potassium
- treatment
ASJC Scopus subject areas
- Nephrology
Cite this
New options for the management of chronic hyperkalemia. / Fried, Linda; Kovesdy, Csaba P.; Palmer, Biff F.
In: Kidney International Supplements, Vol. 7, No. 3, 01.12.2017, p. 164-170.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - New options for the management of chronic hyperkalemia
AU - Fried, Linda
AU - Kovesdy, Csaba P.
AU - Palmer, Biff F.
PY - 2017/12/1
Y1 - 2017/12/1
N2 - Hyperkalemia is a frequently detected electrolyte abnormality that can cause life-threatening complications. Hyperkalemia is most often the result of intrinsic (decreased glomerular filtration rate; selective reduction in distal tubule secretory function; impaired mineralocorticoid activity; and metabolic disturbances, such as acidemia and hyperglycemia) and extrinsic factors (e.g., drugs, such as renin-angiotensin-aldosterone system inhibitors, and potassium intake). The frequent use of renin-angiotensin-aldosterone system inhibitors in patients who are already susceptible to hyperkalemia (e.g., patients with chronic kidney disease, diabetes mellitus, or congestive heart failure) contributes to the high incidence of hyperkalemia. There is a need to understand the causes of hyperkalemia and to be aware of strategies addressing the disorder in a way that provides the most optimal outcome for affected patients. The recent development of 2 new oral potassium-binding agents has led to the emergence of a new paradigm in the treatment of hyperkalemia.
AB - Hyperkalemia is a frequently detected electrolyte abnormality that can cause life-threatening complications. Hyperkalemia is most often the result of intrinsic (decreased glomerular filtration rate; selective reduction in distal tubule secretory function; impaired mineralocorticoid activity; and metabolic disturbances, such as acidemia and hyperglycemia) and extrinsic factors (e.g., drugs, such as renin-angiotensin-aldosterone system inhibitors, and potassium intake). The frequent use of renin-angiotensin-aldosterone system inhibitors in patients who are already susceptible to hyperkalemia (e.g., patients with chronic kidney disease, diabetes mellitus, or congestive heart failure) contributes to the high incidence of hyperkalemia. There is a need to understand the causes of hyperkalemia and to be aware of strategies addressing the disorder in a way that provides the most optimal outcome for affected patients. The recent development of 2 new oral potassium-binding agents has led to the emergence of a new paradigm in the treatment of hyperkalemia.
KW - chronic kidney disease
KW - hyperkalemia
KW - potassium
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=85035785574&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85035785574&partnerID=8YFLogxK
U2 - 10.1016/j.kisu.2017.09.001
DO - 10.1016/j.kisu.2017.09.001
M3 - Review article
C2 - 30675431
AN - SCOPUS:85035785574
VL - 7
SP - 164
EP - 170
JO - Kidney International Supplements
JF - Kidney International Supplements
SN - 2157-1724
IS - 3
ER -